In a large clinical trial comparing four drugs commonly used to treat type 2 diabetes (T2D), researchers from around the country, including at Einstein and Montefiore, found that insulin glargine U-100 and liraglutide performed the best of four drugs approved by the U.S. Food and Drug Administration to maintain blood glucose levels in the recommended range.
Blood glucose management is crucial for keeping people with T2D healthy. All four evaluated drugs were added to treatment with metformin, the first-line drug for treating T2D. Their findings were published online on Sept. 21, 2022, in a pair of papers in the New England Journal of Medicine (NEJM).
Jill Crandall, M.D., professor of medicine and the Jacob A. and Jeanne E. Barkey Chair in Medicine at Einstein, and chief of endocrinology at Einstein and Montefiore, was a coauthor on one of the NEJM papers.